Please login to the form below

Not currently logged in
Email:
Password:

Storm Therapeutics strengthens its board

Professor Paul Workman joins as an independent director

Paul WorkmanDrug discovery group Storm Therapeutics has appointed Professor Paul Workman to join its board.

He said: “I am delighted to be joining the board of Storm and working with the company in this exploding area of biology.

“RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies.

“I look forward to working with the board to help guide Storm’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech.”

Workman currently serves The Institute of Cancer Research as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research UK.

Keith Blundy, CEO, Storm Therapeutics, said: “I am pleased to welcome Paul as indepdent director to Storm’s board.

“Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies such as Piramed.

“We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”

14th November 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics